Attributes | Values |
---|
rdf:type
| |
http://linked.open...gbank/description
| - 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease. [PubChem] (en)
|
http://linked.open...y/drugbank/dosage
| |
http://linked.open...generalReferences
| - # WALSHE JM: Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956 Oct;21(4):487-95. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/13362281 # Walshe JM: The story of penicillamine: a difficult birth. Mov Disord. 2003 Aug;18(8):853-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12889074 # Gong Y, Frederiksen SL, Gluud C: D-penicillamine for primary biliary cirrhosis. Cochrane Database Syst Rev. 2004 Oct 18;(4):CD004789. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15495127 # Suarez-Almazor ME, Spooner C, Belseck E: Penicillamine for rheumatoid arthritis. Cochrane Database Syst Rev. 2000;(2):CD001460. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10796440 # Munro R, Capell HA: Penicillamine. Br J Rheumatol. 1997 Jan;36(1):104-9. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/9117147 (en)
|
http://linked.open...gy/drugbank/group
| |
http://linked.open...drugbank/halfLife
| |
http://linked.open...ugbank/indication
| - For treatment of Wilson's disease, cystinuria and active rheumatoid arthritis. (en)
|
http://linked.open...bank/manufacturer
| |
sameAs
| |
Title
| |
adms:identifier
| |
http://linked.open...mechanismOfAction
| - Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson's disease. From in vitro studies which indicate that one atom of copper combines with two molecules of penicillamine. Penicillamine also reduces excess cystine excretion in cystinuria. This is done, at least in part, by disulfide interchange between penicillamine and cystine, resulting in formation of penicillamine-cysteine disulfide, a substance that is much more soluble than cystine and is excreted readily. Penicillamine interferes with the formation of cross-links between tropocollagen molecules and cleaves them when newly formed. The mechanism of action of penicillamine in rheumatoid arthritis is unknown although it appears to suppress disease activity. Unlike cytotoxic immunosuppressants, penicillamine markedly lowers IgM rheumatoid factor but produces no significant depression in absolute levels of serum immunoglobulins. Also unlike cytotoxic immunosuppressants which act on both, penicillamine in vitro depresses T-cell activity but not B-cell activity. (en)
|
http://linked.open...drugbank/packager
| |
http://linked.open...outeOfElimination
| - Excretion is mainly renal, mainly as disulfides. (en)
|
http://linked.open.../drugbank/synonym
| - (+-)-Penicillamine (en)
- 2-amino-3-Mercapto-3-methylbutyric acid (en)
- 3,3-Dimethylcysteine (en)
- D,L-Penicillamine (en)
- DL-3-Mercaptovaline (en)
- DL-beta-Mercaptovaline (en)
- Penicilamina (en)
- Penicillamina (en)
- Penicillaminum (en)
- Pénicillamine (en)
- beta-Mercaptovaline (en)
- β-Mercaptovaline (en)
|
http://linked.open...k/foodInteraction
| - Food reduces availability, take on an empty stomach. (en)
- Drink liberally. (en)
|
http://linked.open...nk/proteinBinding
| - >80% (bound to plasma proteins) (en)
|
http://linked.open...ynthesisReference
| - Manfred Klaus Joachim Bock, deceased, "Method of producing penicillamine." U.S. Patent US3968154, issued November, 1960. (en)
|
http://linked.open...y/mesh/hasConcept
| |
foaf:page
| |
http://linked.open...ugbank/IUPAC-Name
| |
http://linked.open...gy/drugbank/InChI
| |
http://linked.open...Molecular-Formula
| |
http://linked.open.../Molecular-Weight
| |
http://linked.open...noisotopic-Weight
| |
http://linked.open...y/drugbank/SMILES
| |
http://linked.open.../Water-Solubility
| |
http://linked.open...ogy/drugbank/logP
| |
http://linked.open...ogy/drugbank/logS
| |
http://linked.open...logy/drugbank/pKa
| |
http://linked.open...l/drug/hasATCCode
| |
http://linked.open...nd-Acceptor-Count
| |
http://linked.open...-Bond-Donor-Count
| |
http://linked.open...drugbank/InChIKey
| |
http://linked.open...urface-Area--PSA-
| |
http://linked.open...nk/Polarizability
| |
http://linked.open...bank/Refractivity
| |
http://linked.open...atable-Bond-Count
| |
http://linked.open...ugbank/absorption
| - rapidly but incompletely (en)
|
http://linked.open.../affectedOrganism
| - Humans and other mammals (en)
|
http://linked.open...casRegistryNumber
| |
http://linked.open...drugbank/category
| |
http://linked.open...gbank/containedIn
| |
http://linked.open...k/Bioavailability
| |
http://linked.open...bank/Ghose-Filter
| |
http://linked.open...nk/MDDR-Like-Rule
| |
http://linked.open...ank/Melting-Point
| |
http://linked.open...k/Number-of-Rings
| |
http://linked.open...siological-Charge
| |
http://linked.open...bank/Rule-of-Five
| |
http://linked.open...tional-IUPAC-Name
| |
http://linked.open...strongest-acidic-
| |
http://linked.open...-strongest-basic-
| |